Serum miR-409-3p and miR-325-3p in primaryliver cancer are associated with the efficacy of interventional therapy

Objective To explore the relationship between miR-409-3p and miR-325-3p with the efficacy of interventional therapy in patients with primary liver cancer. Methods Ninety-six patients with primary liver cancer who visited Nanyang Central Hospital from October 2021 to January 2024 were regarded as the liver cancer group. All patients underwent transcatheter arterial chemoembolization(TACE)treatment and were separated into an effective group(complete remission,partial remission)and an ineffective group(disease stability, disease progression)basedon the treatment effect. Totally 91 patients with liver cirrhosis who underwent treatment in our hospital during the same period were selected as liver cancer group and 98 healthy individuals who received physical examinations during the same period were selected as the healthy group. Serum miR-409-3p,miR-325-3p levels were detected and analyzed for their correlation. Logistic regression was applied to analyze the relevant factors affecting the efficacy of TACE treatment. Receiver operating characteristic(ROC) curve was applied to evaluate their predictive value for TACE treatment efficacy of serum miR-409-3p,miR-325-3p levels. Results Compared with the healthy group,the serum level of miR-409-3p and miR-325-3p in the liver cirrhosis group and liver cancer group were reduced(P＜0.05). Compared with the liver cirrhosis group,the serum level of miR-409-3p and miR-325-3p in the liver cancer group were also reduced(P＜0.05). Compared with the effective group,the serum level of miR-409-3p and miR-325-3p in the ineffective group significantly decreased(P＜0.05). There was a positive correlation between serum level of miR-409-3p and of miR-325-3p in patients with primary liver cancer(r=0.472,P＜0.001). The elevated level of miR-409-3p and miR-325-3p were protective factors for ineffective TACE treatment in primary liver cancer patients(P＜0.05). The combination of serum miR-409-3p and miR-325-3p was superior to single prediction in predicting efficacy after TACE treatment in primary liver cancer patients(Zcombination - miR-409-3p=4.556,P＜0.001,Zcombination-miR-325-3p=2.613,P＜0.01). Conclusions The serum level of miR-409-3p as well as miR-325-3p is both reduced in patients with primary liver cancer,and is related to the efficacy of interventional therapy.